CHRS - BioGenerics, In
Form 10-Q Period: MAR.31.18 Date Filed: MAY.10.18
Transcript Split
  
  
     
Move to First Section Move to Last Section
INDEX
ItemizedPage-by-Page
  Form 10-Q (Entire Filing)

Filing Body

Page 1: UNITED STATES

Page 2: COHERUS BIOSCIENCES, INC.

Page 3: CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Page 4: N/A

Page 5: PART I. FINANCIAL INFORMATION

Page 6: Coherus BioSciences, Inc.

Page 7: Coherus BioSciences, Inc.

Page 8: Coherus BioSciences, Inc.

Page 9: Coherus BioSciences, Inc.

Page 10: Foreign Currency

Page 11: Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients

Page 12: Research and Development Expenses

Page 13: Recent Accounting Pronouncements

Page 14: N/A

Page 15: Contingent Consideration

Page 16: Convertible Notes

Page 17: Accrued Liabilities

Page 18: Debt with Conversion and Other Options

Page 19: Purchase Commitments

Page 20: Stock-Based Compensation

Page 21: N/A

Page 22: The interim financial statements included in this Quarterly Report on Form 10-Q and this Management

Page 23: Financial Operations Overview

Page 24: General and Administrative Expense

Page 25: Revenue Recognition

Page 26: Recent Accounting Pronouncements

Page 27: Results of Operations

Page 28: Liquidity and Capital Resources

Page 29: Net cash used in investing activities

Page 30: Funding Requirements

Page 31: Evaluation of Effectiveness of Disclosure Controls and Procedures

Page 32: PART II OTHER INFORMATION

Page 33: You should consider carefully the risks and uncertainties described below, together with all of the

Page 34: We have never generated any revenue from product sales and may never be profitable.

Page 35: We will need to raise substantial additional funding. This additional funding may not be available o

Page 36: Risks Related to the Discovery and Development of Our Product Candidates

Page 37: If we are not able to demonstrate biosimilarity of our biosimilar product candidates to the satisfac

Page 38: The structure of complex proteins used in protein-based therapeutics is inherently variable and high

Page 39: Our product candidates may cause undesirable side effects or have other properties that could delay

Page 40: The development, manufacture and commercialization of biosimilar products under various global regul

Page 41: Regulatory Framework for Biosimilars Outside the U.S.

Page 42: If other biosimilars of pegfilgrastim (Neulasta), adalimumab (Humira), etanercept (Enbrel), ranibizu

Page 43: CHS-1701, our pegfilgrastim (Neulasta) biosimilar candidate, may not be approved in a timely manner

Page 44: Adverse events involving an originator product, or other biosimilars of such originator product, may

Page 45: We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for

Page 46: We are dependent on Orox for the commercialization of our biosimilar product candidates in certain m

Page 47: We are subject to a multitude of manufacturing risks. Any adverse developments affecting the manufac

Page 48: Our reliance on third parties requires us to share our trade secrets, which increases the possibilit

Page 49: If an improved version of an originator product, such as Neulasta, Humira, Enbrel, Lucentis or Eylea

Page 50: We face intense competition and rapid technological change and the possibility that our competitors

Page 51: We may need to enter into alliances with other companies that can provide capabilities and funds for

Page 52: Policies and practices governing the naming of biosimilar product candidates are neither fully estab

Page 53: Our biosimilar product candidates, if approved, could face price competition from other biosimilars

Page 54: N/A

Page 55: N/A

Page 56: So called submarine patents may be granted to our competitors that may significantly alter our launc

Page 57: We may be subject to claims that our employees, consultants, or independent contractors have wrongfu

Page 58: If we are unable to obtain and maintain effective patent rights for our product candidates or any fu

Page 59: Obtaining and maintaining our patent protection depends on compliance with various procedural requir

Page 60: Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our abi

Page 61: If we fail to comply with our obligations in the agreements under which we license intellectual prop

Page 62: Amgen v. Sandoz

Page 63: Risks Related to Our Business Operations

Page 64: Healthcare legislative reform measures may have a material adverse effect on our business and result

Page 65: We may be subject, directly or indirectly, to federal and state healthcare laws, including fraud and

Page 66: The international aspects of our business expose us to business, regulatory, political, operational,

Page 67: We or the third parties upon whom we depend may be adversely affected by earthquakes or other natura

Page 68: Our principal stockholders and management own a significant percentage of our stock and will be able

Page 69: Future sales and issuances of our common stock or rights to purchase common stock, including pursuan

Page 70: We do not intend to pay dividends on our common stock so any returns will be limited to the value of

Page 71: N/A

Page 72: INDEX TO EXHIBITS

Page 73: SIGNATURES

Exhibits

Interactive Data

   CURRENT PAGE
    Download Current Page as a Word Document  Download Current Page as a PDF Document    Download Excel File of Financials